This report addresses studies of the release of active ingredients (diphenhydramine and fluconazole) from a gel base for a medicine for external application for the treatment of allergy complicated by fungal infection; its toxicological and morphological properties were studied. The gel composition was found to be a medicinal formulation providing complete release of the active components from the gel: the quantity of diphenhydramine released in 3 h approached 75%, while the quantity of fluconazole approached 72%. Active substances are easily released from this formation on application to the skin surface, with accumulation of drug to high concentrations at the lesion site. The gel composition was found to belong to class VI, relatively harmless substances, without toxic or cumulative actions. Skin histology results from experimental animals confirmed rapid regeneration of skin lesions on external application of the gel composition.
Similar content being viewed by others
References
D. Rigopoulos and G. Larios, Acta Derm. Venereol., Supplement 216, 7 – 13 (2008).
L. A. Khaertdinova and T. G. Malanicheva, Fundament. Issled., 7 – 1, 211 – 214 (2012).
P. G. Bowler, J. Wound Care, 27, No. 5, 273 – 277 (2018); doi: https://doi.org/10.12968/jowc2018275273.
O. R. Akhmedov, Chemistry for Sustainable Development, No. 25, 341 – 345 (2017); doi: https://doi.org/10.15372/CSD20170401.
N. N. Filimonkova, E. A. Bakhlykova, and M. S. Kolbina, Klin. Dermatol. Venerol., 1, 69 – 77 (2016); doi: https://doi.org/10.17116/klinderma201615169-77.
Z. D. Khadzhieva, V. A. Chumakova, and L. B. Gubanova, Sovrem. Prob. Nauki Obraz., No. 1 – 2, 232 (2015).
V. V. Gladyshev, Kuban. Nauch. Med. Vestn., No. 5 (140), 69 – 73 (2013).
A. N. Mironov, Guidelines for Preclinical Studies of Drugs [in Russian], Grif i K., Moscow (2013), Part 1.
T. A. Gus’kova, Drug Toxicology [in Russian], Moscow (2008), pp. 27 – 30.
A. V. Stefanov, Preclinical Studies of Drugs (Methodological Guidelines) [in Russian], Kiev (2002).
R. K. Lim and K. G. Rinketal, Arch. Int. Pharmacodyn., 130(1), 336 – 353 (1961).
Republic of Uzbekistan Patent No. IAR 05327 (2017).
A. V. Filatova, A. S. Turaev, D. T. Dzhurabaev, and L. B. Azimova, Khim.-Farm. Zh., 54(11), 53 – 56 (2020); doi: https://doi.org/10.30906/0023-1134-2020-54-11-53-56; Pharm. Chem. J., 54(11), 1169 – 1172 (2021).
A. V. Filatova, A. S. Turaev, and N. L. Vypova, Khim.-Farm. Zh., 54(8), 29 – 34 (2020); doi: https://doi.org/10.30906/0023-1134-2020-54-8-29-34; Pharm. Chem. J., 54(8), 822 – 826 (2020).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 56, No. 1, pp. 19 – 24, January, 2022.
Rights and permissions
About this article
Cite this article
Filatova, A.V., Azimova, L.B. & Turaev, A.S. Biopharmaceutical, Toxicological, and Morphological Assessment of an Antiallergenic Medicine for External Application. Pharm Chem J 56, 16–21 (2022). https://doi.org/10.1007/s11094-022-02595-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-022-02595-1